WuXi Biologics, TaiMed rise after FDA approves mAb for HIV

WuXi Biologics Inc. (HKSE:2269) climbed HK$3.15 to HK$61.90 on Wednesday after FDA approved Trogarzo ibalizumab-uiyk, a mAb the

Read the full 182 word article

User Sign In